Dr. Welling on the Efficacy of Nivolumab in HCC

Theodore H. Welling, MD
Published: Wednesday, Oct 04, 2017



Theodore H. Welling, MD, associate professor of surgery, director of the Liver Tumor Program at NYU Langone Health's Perlmutter Cancer Center, discusses the efficacy of nivolumab (Opdivo) for patients with hepatocellular carcinoma (HCC).

The initial findings of CheckMate-040 show that nivolumab was well tolerated and safe. The toxicity profile is better than what is seen currently with other agents, explains Welling. There have been significant responses seen with all subsets of patients.

There have been durable responses, states Welling. The data are still being analyzed to determine what the overall survival will be with the cohorts. Ongoing studies are being conducted to compare nivolumab with other agents.
 


Theodore H. Welling, MD, associate professor of surgery, director of the Liver Tumor Program at NYU Langone Health's Perlmutter Cancer Center, discusses the efficacy of nivolumab (Opdivo) for patients with hepatocellular carcinoma (HCC).

The initial findings of CheckMate-040 show that nivolumab was well tolerated and safe. The toxicity profile is better than what is seen currently with other agents, explains Welling. There have been significant responses seen with all subsets of patients.

There have been durable responses, states Welling. The data are still being analyzed to determine what the overall survival will be with the cohorts. Ongoing studies are being conducted to compare nivolumab with other agents.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x